Cantor Fitzgerald On Amarin Notes 'The FDA's questions and comments were in-line with Street expectations and there were no surprises. Next up after AdCom is the IP debate, and we think AMRN will also prevail here'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/12/2019 17:09